Skip Navigation LinksSkip Navigation Links
Centers for Disease Control and Prevention
Safer Healthier People
Blue White
Blue White
bottom curve
CDC Home Search Health Topics A-Z spacer spacer
spacer
Blue curve MMWR spacer
spacer
spacer


Persons using assistive technology might not be able to fully access information in this file. For assistance, please send e-mail to: mmwrq@cdc.gov. Type 508 Accommodation and the title of the report in the subject line of e-mail.

Errata: Vol. 58, No. 13

In the report, "HIV-Associated Behaviors Among Injecting-Drug Users --- 23 Cities, United States, May 2005--February 2006," errors occurred in the text and table. Following are the corrected text and table. An explanation of changes is available at http://www.cdc.gov/hiv/resources/reports/mmwr/mm5813_err/mm5813_err_qa.htm.

The third sentence of the first paragraph should read: "The results of that analysis indicated that, during that period, 32.8% of participating IDUs reported sharing syringes, and 63.4% had unprotected vaginal sex; 66.3% had been tested for HIV, and 29.7% had participated in an HIV behavioral intervention."

The last sentence of the fifth paragraph should read: "Overall, by demographic characteristic, the highest percentages of participants were men (67.3%), non-Hispanic blacks (46.0%), and persons aged 45--54 years (37.2%)."

The sixth, seventh, and eighth paragraphs should read: "Among the participating IDUs, 32.8% reported sharing syringes, and 58.5% reported sharing injection equipment during the preceding 12 months (Table). Syringes were shared most commonly among non-Hispanic white IDUs (41.1%) and persons aged 18--24 years (45.4%).

Overall, 82.4% of the IDUs reported having vaginal sex, and 63.4% reported having unprotected vaginal sex; 47.8% had more than one opposite-sex partner during the preceding 12 months. The prevalence of having unprotected vaginal sex was highest among those aged 18--24 years (68.4%). The prevalence of having more than one opposite-sex partner was highest among those aged 18--24 years (60.3%) (Table).

During the 12 months preceding their interviews, 66.3% of participants had been tested for HIV infection; the prevalence of testing was lowest among men (64.4%), non-Hispanic whites (62.4%), and persons aged 45--54 years (63.6%). Among the IDUs, 29.7% reported participating in an individual or group HIV behavioral intervention; such participation was least common among non-Hispanic whites (23.4%). HCV testing or diagnosis had been received by 72.7% of participants at some time in their lives; HCV testing was least common among those aged 18--24 years (66.0%) (Table)."

In the first paragraph of the Editorial Note, the second and fourth sentences should read: "The finding that approximately one third of participants reported sharing syringes and over half reported sharing injection equipment (32.8% and 58.5%, respectively) underscores the need to continue to focus HIV prevention strategies on these behaviors despite declines in HIV incidence among IDUs (1)." ... "However, the NHBS data also indicate that approximately half of participants had unprotected vaginal sex (63.4%) or multiple opposite-sex partners (47.8%), suggesting that a substantial proportion of IDUs are at risk for acquiring HIV infection through their sexual behavior in addition to their drug use practices."

In the second paragraph of the Editorial Note, the second sentence should read: "However, only 29.7% of NHBS participants had participated in individual or group HIV behavioral interventions during the preceding 12 months."

TABLE. Estimated percentage* of injecting-drug users (IDUs) engaging in selected behaviors associated with human immunodeficiency virus (HIV) infection during the preceding 12 months, by sex, race/ethnicity, and age group --- National HIV Behavioral Surveillance System, 23 cities,§ United States, May 2005--February 2006

Characteristic

Shared syringes

%

(SE)

Shared injection equipment

%

(SE)

Had vaginal sex

%

(SE)

Had unprotected vaginal sex

%

(SE)

Had more than one opposite-sex partner

%

(SE)

Tested for HIV infection

%

(SE)

Participated in HIV behavioral intervention

%

(SE)

Tested for hepatitis C

%

(SE)

Overall

32.8

58.5

82.4

63.4

47.8

66.3

29.7

72.7

(0.9)

(1.0)

(0.8)

(1.0)

(1.0)

(0.9)

(0.9)

(0.9)

Sex

Men

33.1

58.9

83.5

63.6

51.7

64.4

28.5

74.4

(1.1)

(1.2)

(0.9)

(1.2)

(1.1)

(1.1)

(1.0)

(1.0)

Women

32.4

57.6

80.3

62.9

40.1

69.8

32.3

69.5

(1.6)

(1.9)

(1.5)

(1.8)

(1.6)

(1.6)

(1.7)

(1.7)

Race/Ethnicity

White, non-Hispanic

41.1

65.9

82.0

65.0

48.6

62.4

23.4

75.8

(1.7)

(1.7)

(1.3)

(1.7)

(1.8)

(1.7)

(1.5)

(1.5)

Black, non-Hispanic

29.9

55.8

85.5

65.1

52.5

66.2

31.1

69.2

(1.2)

(1.4)

(1.0)

(1.3)

(1.3)

(1.2)

(1.2)

(1.2)

Hispanic

30.1

56.7

77.3

58.7

39.1

70.2

33.3

75.1

(2.1)

(2.5)

(2.3)

(2.5)

(2.3)

(2.1)

(2.2)

(2.1)

Other**

37.5

63.5

82.5

60.2

49.2

64.0

35.1

78.5

(5.0)

(4.8)

(3.4)

(4.6)

(5.3)

(4.5)

(5.1)

(3.9)

Age group (yrs)

18--24

45.4

70.5

88.7

68.4

60.3

72.6

24.4

66.0

(4.8)

(4.3)

(2.6)

(3.9)

(4.4)

(3.3)

(4.7)

(4.1)

25--34

40.2

63.0

87.6

65.5

58.9

70.2

29.9

69.0

(2.3)

(2.3)

(1.6)

(2.4)

(2.0)

(1.8)

(2.2)

(2.1)

35--44

33.1

59.9

84.4

67.5

48.8

67.4

32.5

67.9

(1.6)

(1.8)

(1.5)

(1.7)

(1.7)

(1.6)

(1.7)

(1.8)

45--54

33.0

58.5

80.8

62.8

44.7

63.6

29.9

77.7

(1.4)

(1.6)

(1.3)

(1.6)

(1.6)

(1.5)

(1.4)

(1.4)

≥55

24.9

51.7

71.1

49.6

37.7

65.1

24.3

79.9

(2.5)

(3.0)

(2.8)

(2.7)

(2.8)

(2.8)

(2.4)

(2.1)

* Percentages were weighted to adjust for differences in recruitment, the size of participant IDU peer networks, and the size of the IDU population in each city.

Sharing syringes was defined as "using needles that might have already been used by someone else," and sharing injection equipment was defined as using equipment such as cookers, cottons, or water used to rinse needles or prepare drugs "that someone else used." Unprotected vaginal sex was defined as "sex without a condom." Persons tested for HIV infection include those with results that were negative, indeterminate, or unknown. Participating in an individual or group HIV behavioral intervention did not include counseling received as part of an HIV test. Testing for hepatitis C virus infection was measured as ever tested or ever received a diagnosis of hepatitis C.

§ Atlanta, Georgia; Baltimore, Maryland; Boston, Massachusetts; Chicago, Illinois; Dallas, Texas; Denver, Colorado; Detroit, Michigan; Fort Lauderdale, Florida; Houston, Texas; Las Vegas, Nevada; Los Angeles, California; Miami, Florida; Nassau-Suffolk, New York; New Haven, Connecticut; New York, New York; Newark, New Jersey; Norfolk, Virginia; Philadelphia, Pennsylvania; San Diego, California; San Francisco, California; San Juan, Puerto Rico; St. Louis, Missouri; and Seattle, Washington.

Standard error.

** Includes American Indian/Alaska Natives, Asians, Native Hawaiian or other Pacific Islanders, persons of multiple race, and those for whom race/ethnicity information was missing.

Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.


References to non-CDC sites on the Internet are provided as a service to MMWR readers and do not constitute or imply endorsement of these organizations or their programs by CDC or the U.S. Department of Health and Human Services. CDC is not responsible for the content of pages found at these sites. URL addresses listed in MMWR were current as of the date of publication.

All MMWR HTML versions of articles are electronic conversions from typeset documents. This conversion might result in character translation or format errors in the HTML version. Users are referred to the electronic PDF version (http://www.cdc.gov/mmwr) and/or the original MMWR paper copy for printable versions of official text, figures, and tables. An original paper copy of this issue can be obtained from the Superintendent of Documents, U.S. Government Printing Office (GPO), Washington, DC 20402-9371; telephone: (202) 512-1800. Contact GPO for current prices.

**Questions or messages regarding errors in formatting should be addressed to mmwrq@cdc.gov.

Date last reviewed: 12/23/2009

HOME  |  ABOUT MMWR  |  MMWR SEARCH  |  DOWNLOADS  |  RSSCONTACT
POLICY  |  DISCLAIMER  |  ACCESSIBILITY

Safer, Healthier People

Morbidity and Mortality Weekly Report
Centers for Disease Control and Prevention
1600 Clifton Rd, MailStop E-90, Atlanta, GA 30333, U.S.A

USA.GovDHHS

Department of Health
and Human Services